vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and Phreesia, Inc. (PHR). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $120.3M, roughly 1.7× Phreesia, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 3.5%, a 53.8% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $12.2M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.
IDYA vs PHR — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $120.3M |
| Net Profit | $119.2M | $4.3M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | 3.1% |
| Net Margin | 57.4% | 3.5% |
| Revenue YoY | — | 12.7% |
| Net Profit YoY | 330.1% | 129.7% |
| EPS (diluted) | $1.33 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $120.3M | ||
| Q3 25 | $207.8M | $117.3M | ||
| Q2 25 | — | $115.9M | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — | ||
| Q3 22 | $29.7M | — |
| Q4 25 | — | $4.3M | ||
| Q3 25 | $119.2M | $654.0K | ||
| Q2 25 | — | $-3.9M | ||
| Q3 24 | $-51.8M | — | ||
| Q2 24 | $-52.8M | — | ||
| Q1 24 | $-39.6M | — | ||
| Q3 22 | $1.6M | — |
| Q4 25 | — | 3.1% | ||
| Q3 25 | 52.2% | -1.3% | ||
| Q2 25 | — | -2.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 2.2% | — |
| Q4 25 | — | 3.5% | ||
| Q3 25 | 57.4% | 0.6% | ||
| Q2 25 | — | -3.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 5.4% | — |
| Q4 25 | — | $0.07 | ||
| Q3 25 | $1.33 | $0.01 | ||
| Q2 25 | — | $-0.07 | ||
| Q3 24 | $-0.60 | — | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | — | ||
| Q3 22 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $106.4M |
| Total DebtLower is stronger | — | $3.4M |
| Stockholders' EquityBook value | $1.1B | $320.3M |
| Total Assets | $1.2B | $423.5M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $106.4M | ||
| Q3 25 | $786.9M | $98.3M | ||
| Q2 25 | — | $90.9M | ||
| Q3 24 | $920.0M | — | ||
| Q2 24 | $701.7M | — | ||
| Q1 24 | $698.8M | — | ||
| Q3 22 | $386.2M | — |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $4.6M | ||
| Q2 25 | — | $6.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | — | $320.3M | ||
| Q3 25 | $1.1B | $298.0M | ||
| Q2 25 | — | $282.2M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $931.7M | — | ||
| Q1 24 | $935.3M | — | ||
| Q3 22 | $368.8M | — |
| Q4 25 | — | $423.5M | ||
| Q3 25 | $1.2B | $408.6M | ||
| Q2 25 | — | $400.4M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $973.7M | — | ||
| Q1 24 | $961.5M | — | ||
| Q3 22 | $410.9M | — |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.02× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $15.5M |
| Free Cash FlowOCF − Capex | $142.2M | $12.2M |
| FCF MarginFCF / Revenue | 68.4% | 10.1% |
| Capex IntensityCapex / Revenue | 0.0% | 2.7% |
| Cash ConversionOCF / Net Profit | 1.19× | 3.62× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.5M | ||
| Q3 25 | $142.2M | $14.8M | ||
| Q2 25 | — | $14.8M | ||
| Q3 24 | $-49.2M | — | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-43.8M | — | ||
| Q3 22 | $-24.2M | — |
| Q4 25 | — | $12.2M | ||
| Q3 25 | $142.2M | $13.1M | ||
| Q2 25 | — | $11.3M | ||
| Q3 24 | $-49.7M | — | ||
| Q2 24 | $-33.9M | — | ||
| Q1 24 | $-45.1M | — | ||
| Q3 22 | $-25.3M | — |
| Q4 25 | — | 10.1% | ||
| Q3 25 | 68.4% | 11.1% | ||
| Q2 25 | — | 9.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -85.1% | — |
| Q4 25 | — | 2.7% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | — | 3.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 3.7% | — |
| Q4 25 | — | 3.62× | ||
| Q3 25 | 1.19× | 22.68× | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -14.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
PHR
| Subscription And Services | $55.5M | 46% |
| Network Solutions | $37.4M | 31% |
| Payment Processing Fees | $27.4M | 23% |
